Trending

News

News

Roche, Isis sign $392m Huntington’s disease alliance

Roche and Isis have agreed to work together to discover and develop drugs for the genetic brain disorder, Huntington’s disease. Roche has formed an alliance with Isis Pharmaceuticals to develop treatments for the genetic brain disorder, Huntington’s…

X

Roche, Isis sign $392m Huntington’s disease alliance

https://pharmaphorum.com/news/roche_isis_sign_392m_huntingtons_disease_alliance/

FDA approves return of morning sickness drug

A generic version of a morning sickness drug withdrawn from the market 30 years ago has been approved by the US FDA for a re-launch this summer. The US FDA has approved a generic version of a morning sickness treatment for pregnant women that was…

X

FDA approves return of morning sickness drug

https://pharmaphorum.com/news/fda_approves_return_of_morning_sickness_drug/

Janssen’s leukemia drug receives third FDA breakthrough therapy designation

The US FDA has granted J&J’s subsidiary, Janssen, with its third oncology breakthrough therapy designation. Janssen and Pharmacyclics have announced that the US FDA has granted a third Breakthrough Therapy…

X

Janssen’s leukemia drug receives third FDA breakthrough therapy designation

https://pharmaphorum.com/news/janssens_leukemia_drug_receives_third_fda_breakthrough_therapy_designation/

BMS appoints new chief scientific officer

Bristol-Myers Squibb has revealed the company’s new EVP / CSO following Elliot Sigal’s announcement of retirement effective from the end of June 2013. Bristol-Myers Squibb has announced that Francis Cuss is to be the company’s new executive vice president and…

X

BMS appoints new chief scientific officer

https://pharmaphorum.com/news/bms_appoints_new_chief_scientific_officer/

Mixed phase 3 results for AstraZeneca’s arthritis drug

Find out the results of phase 3 clinical trials of AstraZeneca’s rheumatoid arthritis drug, fostamatinib. AstraZeneca has announced mixed results for phase 3 clinical trials that were evaluating the safety and efficacy of…

X

Mixed phase 3 results for AstraZeneca’s arthritis drug

https://pharmaphorum.com/news/mixed_phase_3_results_for_astrazenecas_arthritis_drug/

Astellas, Ambrx in US $300m cancer antibody agreement

Japanese pharma company Astellas has entered into an antibody agreement with US-based Ambryx, for the development of antibody drug conjugates to be used in cancer treatments. Astellas Pharma has entered into a collaboration with Ambrx for the discovery and development of novel antibody…

X

Astellas, Ambrx in US $300m cancer antibody agreement

https://pharmaphorum.com/news/astellas_ambrx_in_us_300m_cancer_antibody_agreement/

GSK seeks to expand use of lupus drug Benlysta

GSK are seeking to expand the use of Benlysta, which is currently approved to treat lupus, through the launch of phase 3 clinical trials. GlaxoSmithKline has announced the start of phase 3 clinical trials to evaluate Benlysta in treating a particular type of…

X

GSK seeks to expand use of lupus drug Benlysta

https://pharmaphorum.com/news/gsk_seeks_to_expand_use_of_lupus_drug_benlysta/

Obama launches new brain research initiative

A new research initiative has been launched by President Barrack Obama to further understand the human brain and find new ways to treat brain disorders. The White House has unveiled a new initiative to revolutionise the understanding of the human brain and uncover new ways to…

X

Obama launches new brain research initiative

https://pharmaphorum.com/news/obama_launches_new_brain_research_initiative/

GSK flu vaccine gets marketing go ahead in UK, Germany

The UK and Germany are the first European countries to approve GSK’s four-strain influenza vaccine, which are expected to be available in time for the 2013/2014 flu season. GSK has announced the marketing authorization of its quadrivalent (four-strain) influenza vaccine in Germany and…

X

GSK flu vaccine gets marketing go ahead in UK, Germany

https://pharmaphorum.com/news/gsk_flu_vaccine_gets_marketing_go_ahead_in_uk_germany/

«< 672 673 674 675 676 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com